Scleroderma drug gets fast-tracked in the US 

Fibrous dysplasia disease

The US Food and Drug Administration (FDA) has granted Fast Track Designation for Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma). 

The Fast Track Designation was granted based on results of a Phase II study which indicated that treatment of scleroderma patients with FT011 for 12 weeks resulted in a clinically meaningful improvement in 60% of patients treated with FT011 400mg and 20% of patients in the FT011 200mg group compared with 10% in the placebo group. 

FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs. It targets an important but previously undrugged membrane GPCR receptor, GPR68, with an extensive body of data demonstrating promising efficacy in multiple models of fibrotic disease. 

Transcriptomic research has validated the mechanism of action and demonstrated that treatment with FT011 results in reversal in the activation of genetic markers associated with fibrosis, providing potential for a precision therapy. 

Professor Darren Kelly, Certa Therapeutics CEO and Founder, said: We are thrilled to have received Fast Track Designation which supports further acceleration of the FT011 clinical development programme. It is also provides validation of FT011’s potential to offer patients with scleroderma the first anti-fibrotic and disease modifying treatment of this type.” 

We know that this debilitating and life-threatening disease can severely impact the lives of patients and to date existing treatments only focus on the relief and management of symptoms, whereas FT011 precisely targets the root cause of fibrosis and has the potential to offer treatment across multiple organs within these patients.” 

Certa is progressing towards a pivotal clinical trial of FT011 as a treatment for scleroderma. 

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free